News - Latest
97 news items
Changes to product information must be made more quickly
Within Europe agreements are regularly made regarding changes to information on medicinal products. In many cases it takes too ...
Year-end withdrawals medicines for human use
Withdrawal requests for (parallel) marketing authorisations per 31 December, the so-called 'year-end withdrawals' for medicines ...
8th edition Regulatory Science Magazine
Today the Medicine Evaluation Board (MEB) publishes the 8th edition of its Regulatory Science Magazine. This edition focuses on ...
MEB and ZIN start pilot to accelerate access to innovative medicines
Accelerating patient access to reimbursable innovative medicines has been on the wish list of the government, patient ...
Amended policy relating to patented indications
The Medicines Evaluation Board (MEB) will no longer publish the full product information about the active substance of generic ...
The MEB in 2018: A focus on core tasks
'At the MEB life is never boring'. This is how MEB chair Ton de Boer and director Hugo Hurts start their review of 2018. This ...
Change in policy on patient information due to judgement by the European Court of Justice
The Medicines Evaluation Board (MEB) will no longer publish the full product information about the active substance of generic ...
Science Magazine, 7th edition: Rapid developments in advanced therapies and the vision for Regulatory Science 2025
The MEB, the Dutch medicines authority, publishes the seventh edition of its Regulatory Science Magazine today. This edition ...
Brexit: Notification by the European Commission/EMA/CMDh and CMDv about Brexit and EU rules for batch control of medicinal products
On 25 February 2019 the European Commission (EC) published a notice on the European rules for batch control testing of medicinal ...
MEB fee rate change as of January 2019
The Medicines Evaluation Board (MEB) is increasing the fee rates for authorisation applications, authorisation changes and the ...